We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential enable/disable

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name	Webedition CMS
Purpose	This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name	econda
Purpose	Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

Statistics enable/disable

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name	econda
Purpose	Statistics

External media enable/disable

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name	YouTube
Purpose	Show YouTube content
Name	Twitter
Purpose	activate Twitter Feeds

Research

PET/MRI

PET/MR in radiation treatment planning

Ansprechpartner: Dr. med. Bettina Beuthien-Baumann

The Radiotracer PSMA (Prostate-specific-membrane-antigen), a development of the Radiopharmacy group of the DKFZ, has emerged as a sensitive imaging probe for staging of prostate cancer with hybrid PET. Prospective work will investigate the possible integration of PSMA-PET/MR into radiation treatment planning. Optimized PET/MR-protocols could translate into individualized radiation treatment plans in patients with prostate cancer. This work will be implemented in close collaboration with the Radiation Oncology Department of the University Hospital Heidelberg.

Motion correction

Fig.1 Lung phantom: A: "blurring" of lung lesions due to periodic ventilation B: visualization of distinct lesions after MR-based motion correction
© dkfz.de

Ansprechpartner: Dr. med. Bettina Beuthien-Baumann, Dr. med. Oliver Sedlaczek

Even shallow breathing induces blurring of PET-data, which influences identifiability and quantitative evaluation, especially of small lesions (Fig. 1). Concurrent acquired MR-data can be used to correct for periodic motion of thorax and upper abdomen [1]. The feasibility of generating motion corrected PET-data, their influence on the detectability of small malignant lesions and the impact on the staging of oncologic diseases like bronchial carcinoma or malignancies of the upper abdomen, are investigated.

Selected Publications

1. Rank CM, Heußer T, Wetscherek A, Freitag M, Sedlaczek O, Schlemmer H, Kachelrieß M. Respiratory motion compensation for simultaneous PET/MR based on highly undersampled MR data. MedPhys (2016) 43:6234-6245.

Links

http://onlinelibrary.wiley.com/doi/10.1118/1.4966128/epdf